GLP-1 medicines and sleep apnoea: the honest picture
Obstructive sleep apnoea, where the airway partly or fully closes during sleep, is common in people carrying extra weight, because extra tissue around the neck narrows the airway. Losing weight is one of the few things that can actually reduce sleep apnoea severity, and a 10 percent drop in body weight can cut the apnoea count by about a quarter to a third. The SURMOUNT-OSA trial of tirzepatide in adults with obesity and moderate-to-severe sleep apnoea found a large drop in the apnoea count compared with placebo, on top of weight loss. Semaglutide has less direct apnoea-count evidence so far, mostly from observational data. The honest line is this: these medicines can help sleep apnoea mainly through weight loss, they are not a replacement for CPAP, and many people still need CPAP even after losing weight.
If you carry extra weight and you snore loudly, wake tired, or feel sleepy in the day, you may have heard of obstructive sleep apnoea, or OSA. In OSA, the airway partly or fully closes during sleep, so breathing stops and starts again, sometimes many times an hour. It is very common in people with obesity, because extra tissue around the neck narrows the airway. Now that GLP-1 medicines like tirzepatide and semaglutide are being used for weight loss, a fair question comes up: can these drugs help sleep apnoea too? The honest answer has three parts. First, losing weight is one of the few things that can truly reduce OSA severity, because it removes the root cause, the narrowed airway. Second, the SURMOUNT-OSA trial of tirzepatide showed a large drop in the apnoea count in adults with obesity and moderate-to-severe OSA. Third, this benefit is mostly driven by weight loss, it is not a cure, and CPAP remains the standard treatment that keeps the airway open at night. This guide is honest about what the trials showed and what they did not.
The baseline: weight loss reduces sleep apnoea, and tirzepatide showed a large AHI drop in SURMOUNT-OSA
Doctors measure OSA severity with the apnoea-hypopnea index, or AHI, the number of breathing pauses per hour. StatPearls lists the thresholds: mild is 5 to 15 events per hour, moderate is greater than 15 to 30, and severe is greater than 30. StatPearls also states that OSA in adults is most commonly associated with obesity, male sex, and advancing age, because extra weight, especially around the neck, narrows the airway. So weight is the big lever. A landmark trial funded by the US National Institutes of Health found that even modest reductions in body weight are associated with changes in obstructive sleep apnea, with a 10 percent reduction in body weight predicting an approximate change of 26 to 32 percent in the apnea-hypopnea index. This is why weight loss, by any method, sits at the heart of OSA care. The key drug trial is SURMOUNT-OSA, published in the New England Journal of Medicine in 2024. It studied tirzepatide in adults with obesity and moderate-to-severe OSA in two groups: people not using PAP therapy (trial 1) and people already using PAP (trial 2). After 52 weeks, in trial 1 the apnoea count fell by 25.3 events per hour with tirzepatide versus 5.3 with placebo, an estimated treatment difference of -20.0 events per hour. In trial 2, the count fell by 29.3 with tirzepatide versus 5.5 with placebo, a treatment difference of -23.8 events per hour. The trial concluded that among persons with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure and improved sleep-related patient-reported outcomes. A 2025 meta-analysis of incretin-based therapies (liraglutide and tirzepatide) agreed, finding that incretin-based therapies were associated with AHI reduction, with a mean change of -14.45 events per hour, and that weight reduction through incretin-based therapies improves AHI in OSA. The honest part is that this benefit comes mostly through weight loss, not through some separate airway magic, and weight loss alone is rarely a complete cure. StatPearls puts it plainly: although weight loss is recommended and can often decrease the severity of OSA, it is usually not curative. CPAP, the machine that gently pushes air to keep the airway open, remains the most effective treatment for adults with OSA, and an American Academy of Sleep Medicine guideline gives a strong recommendation that clinicians use PAP, compared to no therapy, to treat OSA in adults with excessive sleepiness.
GLP-1 medicines cure sleep apnoea, so you can stop using CPAP once you lose weight.
VerdictNot supported. Losing weight, including with GLP-1 medicines, can reduce OSA severity, but StatPearls states plainly that although weight loss is recommended and can often decrease the severity of OSA, it is usually not curative. In the SURMOUNT-OSA trial, tirzepatide produced a large drop in the apnoea count, a treatment difference of about 20 to 24 events per hour beyond placebo, and many people still had OSA at the end of the year. CPAP remains the most effective treatment for adults with OSA, and the American Academy of Sleep Medicine gives a strong recommendation to use PAP for OSA with excessive sleepiness. The same guideline notes OSA is a chronic disease that rarely resolves except with substantial weight loss or successful corrective surgery. So the honest position is: GLP-1 medicines can help OSA, mainly by helping you lose weight, but they are not a replacement for CPAP, and the decision to reduce or stop CPAP belongs with your sleep doctor after a repeat sleep study, not on your own.
Working with your doctor on sleep apnoea while on a GLP-1 medicine
- Keep using CPAP if it has been prescribed. CPAP is the most effective treatment for adults with OSA, and the AASM gives a strong recommendation to use it for OSA with excessive sleepiness. Do not stop CPAP on your own just because the scale is moving.
- Treat the weight loss as the main OSA lever. A US NIH-funded trial found a 10 percent drop in body weight predicts about a 26 to 32 percent drop in the apnoea count. Steady, sustainable loss matters more than speed.
- Get a proper diagnosis and repeat sleep study. In-laboratory polysomnography is the gold standard for OSA. After meaningful weight loss, ask your sleep doctor for a repeat study to see if the AHI has truly improved and whether CPAP pressure needs adjusting.
- Your doctor decides medicine and dose. Whether tirzepatide, semaglutide, or another medicine is right for your OSA and weight depends on your full health picture. Never start, change, or stop a GLP-1 dose on your own.
- Add simple sleep habits. Sleep on your side, avoid alcohol and sedatives before bed, keep a regular sleep time, and treat nasal blockage. These support CPAP and weight loss, they do not replace them.
- Watch for the honest limits. The benefit is mostly weight-loss driven, OSA is usually not curative, and a single trial, even a strong one like SURMOUNT-OSA, is not the whole story. Long-term data are still building. Bring day-to-day sleepiness and snoring changes to your doctor, not just the number on the scale.
The bottom line
GLP-1 medicines can help obstructive sleep apnoea, but mostly the honest, simple way: by helping you lose weight, which opens the narrowed airway. A 10 percent drop in body weight predicts about a 26 to 32 percent drop in the apnoea count, and the SURMOUNT-OSA trial of tirzepatide showed a large AHI reduction beyond placebo in adults with obesity and moderate-to-severe OSA. Semaglutide has less direct apnoea-count evidence so far, mostly observational links to lower new-onset OSA risk. The honest limits matter: this benefit is weight-loss driven, OSA is usually not curative, and CPAP remains the most effective treatment and the AASM-recommended standard. So do not throw out the CPAP machine when the scale drops, and do not let a headline turn one trial into a cure. Use CPAP if it is prescribed, aim for steady weight loss with your doctor's plan, and ask for a repeat sleep study before any change in therapy. Burnie can help you log food and see your daily calorie deficit to support that weight loss, but medicine, CPAP, and sleep-study decisions belong with your doctor.